Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Research & Development: 2009-2025

Historic Research & Development for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $7.5 million.

  • Northwest Biotherapeutics' Research & Development fell 8.36% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 6.08%. This contributed to the annual value of $34.9 million for FY2024, which is 25.81% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Research & Development stood at $7.5 million for Q3 2025, which was up 0.27% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Research & Development peaked at $13.6 million during Q2 2022, and registered a low of $3.7 million during Q3 2021.
  • Its 3-year average for Research & Development is $7.8 million, with a median of $7.5 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first slumped by 78.78% in 2021, then soared by 150.32% in 2022.
  • Northwest Biotherapeutics' Research & Development (Quarterly) stood at $4.2 million in 2021, then soared by 123.41% to $9.4 million in 2022, then declined by 20.30% to $7.5 million in 2023, then skyrocketed by 41.17% to $10.5 million in 2024, then decreased by 8.36% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $7.4 million for Q2 2025, and $8.4 million during Q1 2025.